EGFR and neoplasm: The bispecific T-cell engager (BiTE) was composed of two single chain antibodies (scFV) that targeted the tumour-specific EGFR and CD3 on the T-cell receptor to activate T-cells and bring the complex close to the tumour cell for improved elimination.